Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6726MR)

This product GTTS-WQ6726MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6726MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5753MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ13283MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ3325MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ9404MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Iomab-B
GTTS-WQ15908MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ5786MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ1921MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ13155MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW